CUPID 1: MYDICAR ® in Patients With Advanced Heart Failure Continue to Demonstrate Improvement in Clinical Outcomes Compared to Optimal Therapy 9 Months Post-Dose

The phase 2 study compared AAV1/SERCA2a (MYDICAR®) to placebo (placebo plus optimal medical therapy) in 39 stable advanced HF patients (NYHA Class III/IV, LVEF ≤35%, VO2 max ≤20 mL/kg/min) (25 active:14 placebo).